Altrius Capital Management Inc Boosts Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Altrius Capital Management Inc grew its position in Bristol-Myers Squibb (NYSE:BMY) by 4.0% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 46,609 shares of the biopharmaceutical company’s stock after buying an additional 1,785 shares during the quarter. Altrius Capital Management Inc’s holdings in Bristol-Myers Squibb were worth $2,981,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Bessemer Group Inc. lifted its stake in Bristol-Myers Squibb by 17.2% in the 2nd quarter. Bessemer Group Inc. now owns 96,396 shares of the biopharmaceutical company’s stock worth $6,164,000 after purchasing an additional 14,149 shares in the last quarter. Delta Asset Management LLC TN lifted its position in Bristol-Myers Squibb by 4.6% during the second quarter. Delta Asset Management LLC TN now owns 70,386 shares of the biopharmaceutical company’s stock worth $4,501,000 after buying an additional 3,072 shares in the last quarter. WFA of San Diego LLC acquired a new position in Bristol-Myers Squibb during the second quarter worth $76,000. Davis R M Inc. grew its holdings in Bristol-Myers Squibb by 12.2% in the 2nd quarter. Davis R M Inc. now owns 11,883 shares of the biopharmaceutical company’s stock valued at $760,000 after buying an additional 1,289 shares in the last quarter. Finally, Great West Life Assurance Co. Can increased its stake in shares of Bristol-Myers Squibb by 4.0% in the 2nd quarter. Great West Life Assurance Co. Can now owns 2,605,303 shares of the biopharmaceutical company’s stock worth $167,557,000 after acquiring an additional 99,690 shares during the last quarter. 74.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BMY has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft started coverage on shares of Bristol-Myers Squibb in a report on Thursday, November 9th. They issued a “hold” rating and a $55.00 price objective for the company. Bank of America cut their price target on shares of Bristol-Myers Squibb from $85.00 to $80.00 and set a “buy” rating for the company in a report on Friday, July 28th. The Goldman Sachs Group decreased their price objective on Bristol-Myers Squibb from $81.00 to $69.00 and set a “buy” rating on the stock in a report on Monday, October 30th. William Blair downgraded Bristol-Myers Squibb from an “outperform” rating to a “market perform” rating in a research report on Friday, October 27th. Finally, Morgan Stanley lowered their price target on Bristol-Myers Squibb from $56.00 to $50.00 and set an “underweight” rating for the company in a report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $63.59.

Bristol-Myers Squibb Stock Down 2.8 %

Shares of Bristol-Myers Squibb stock traded down $1.44 during trading hours on Monday, reaching $49.40. 9,773,258 shares of the company were exchanged, compared to its average volume of 9,659,062. The firm has a market cap of $100.52 billion, a PE ratio of 12.63, a PEG ratio of 1.62 and a beta of 0.38. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.07 and a current ratio of 1.18. Bristol-Myers Squibb has a 1 year low of $48.78 and a 1 year high of $81.43. The stock’s fifty day moving average is $55.60 and its 200 day moving average is $60.85.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.00 earnings per share for the quarter, topping the consensus estimate of $1.76 by $0.24. The company had revenue of $10.97 billion for the quarter, compared to the consensus estimate of $10.96 billion. Bristol-Myers Squibb had a return on equity of 51.59% and a net margin of 18.44%. Bristol-Myers Squibb’s revenue was down 2.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.99 EPS. As a group, equities research analysts forecast that Bristol-Myers Squibb will post 7.56 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 4.62%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 57.87%.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Ann Powell sold 17,986 shares of Bristol-Myers Squibb stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the completion of the sale, the executive vice president now directly owns 27,868 shares of the company’s stock, valued at approximately $1,706,915. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.